Kyrgyzstan vs Puerto Rico: Prevalence rate of hypertension in women aged 30-79
Kyrgyzstan
43.2
in 2019
Puerto Rico
43.2
in 2019
Kyrgyzstan rank
34th
Puerto Rico rank
34th
Prevalence rate of hypertension in women aged 30-79 over time
- Kyrgyzstan
- Puerto Rico
How they compare
Kyrgyzstan currently reports 43.2 against 43.2 in Puerto Rico, a difference of 0.
The two have swapped places 1 time across 30 shared years of data; in 1990 it was Kyrgyzstan ahead.
Kyrgyzstan ranks 34th and Puerto Rico ranks 34th of 195 countries.
Kyrgyzstan has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Kyrgyzstan | Puerto Rico | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 39.84 | 37.57 | 2.27 | Kyrgyzstan |
| 2000s | 41 | 40.01 | 0.99 | Kyrgyzstan |
| 2010s | 42.79 | 42.6 | 0.19 | Kyrgyzstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in women aged 30-79, Kyrgyzstan or Puerto Rico?
- Kyrgyzstan, at 43.2 against 43.2 in Puerto Rico as of 2019.
- What is the difference in prevalence rate of hypertension in women aged 30-79 between Kyrgyzstan and Puerto Rico?
- 0, with Kyrgyzstan ahead.
- How many years of comparable data are there for Kyrgyzstan and Puerto Rico?
- 30 years are reported by both, from 1990 to 2019.
- How do Kyrgyzstan and Puerto Rico rank globally for prevalence rate of hypertension in women aged 30-79?
- Kyrgyzstan ranks 34th and Puerto Rico ranks 34th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in women aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of female population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.